Trastuzumab deruxtecan shows early promise in patients with non-breast/gastric cancers

(American Association for Cancer Research) A HER2-targeted antibody-drug conjugate, fam-trastuzumab deruxtecan-nxki (Enhertu), showed signs of clinical activity in multiple non-breast/non-gastric cancer types, according to results from a phase I study.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news